{"id":"W3093265161","doi":"10.1016/s0140-6736(10)60892-6","title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial","year":2010,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1636,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Susan G. Komen; Cancer Research Society; AstraZeneca","keywords":"Olaparib; Medicine; Tolerability; Breast cancer; Cohort; PARP inhibitor; Internal medicine; BRCA mutation; Oncology; Adverse effect; Nausea; Cancer; Poly ADP ribose polymerase; Polymerase; Biology; Genetics","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}